Entinostat (MS-275)

Name: Entinostat (MS-275)
Brand: Selleck Chemicals
SKU: S1053
Rating: 5 (288 reviews)

For research use only.

Catalog No.S1053 Synonyms: SNDX-275

288 publications

CAS No. 209783-80-2

Entinostat (MS-275, SNDX-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Entinostat induces autophagy and apoptosis. Phase 3.

Selleck's Entinostat (MS-275) has been cited by 288 publications

Nat Biotechnol, 2020, 10.1038/s41587-019-0388-4

PubMed: 31959954 ( click the link to review the publication )

Cell, 2019, 178(5):1115-1131

PubMed: 31442404 ( click the link to review the publication )

Cell, 2019, 176(1-2):198-212

PubMed: 30503211 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Cancer Cell, 2016, 29(3):311-323

PubMed: 26977882 ( click the link to review the publication )

Nat Biotechnol, 2015, 10.1038/nbt.3130

PubMed: 25751058 ( click the link to review the publication )

Nat Immunol, 2014, 15(5):439-48

PubMed: 24681565 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(3):255-65

PubMed: 21258344 ( click the link to review the publication )

Nat Protoc, 2020, 15(3):1209-1236

PubMed: 32051612 ( click the link to review the publication )

EMBO Rep, 2020, 4;21(3):e49254

PubMed: 32009295 ( click the link to review the publication )

EMBO Rep, 2020, 21:e50162

PubMed: 32314873 ( click the link to review the publication )

Theranostics, 2020, 10(21):9644-9662

PubMed: 32863951 ( click the link to review the publication )

J Autoimmun, 2020, 108:102379

PubMed: 31883829 ( click the link to review the publication )

Cells, 2020, 21;9(5):E1280

PubMed: 32455774 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

J Transl Med, 2020, 7;18(1):159

PubMed: 32264925 ( click the link to review the publication )

Cell Signal, 2020, 70:109573

PubMed: 32087304 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2020, 146(2):343-356

PubMed: 31932908 ( click the link to review the publication )

PLoS One, 2020, 15;15(5):e0232985

PubMed: 32413049 ( click the link to review the publication )

Theranostics, 2020, 10(16):7351-7368

PubMed: 32641996 ( click the link to review the publication )

Oncol Lett, 2020, 19(1):460-468

PubMed: 31897159 ( click the link to review the publication )

Sci Adv, 2020, 6(29):eaba1941

PubMed: 32832623 ( click the link to review the publication )

Pathol Res Pract, 2020, 216(4):152867

PubMed: 32067803 ( click the link to review the publication )
Neoplasia, 2020, 22(9):376-389

PubMed: 32629178 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(14):14174-14188

PubMed: 32692721 ( click the link to review the publication )

JCI Insight, 2020, 5(4)

PubMed: 32102981 ( click the link to review the publication )

Eur J Immunol, 2020, 10.1002/eji.202048566

PubMed: 32644192 ( click the link to review the publication )

Gastroenterology, 2019, 156(1):187-202

PubMed: 30267710 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4192

PubMed: 31519896 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5324

PubMed: 31757943 ( click the link to review the publication )

Nucleic Acids Res, 2019, 10.1093/nar/gkz1136

PubMed: 31799598 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31227503 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.211110

PubMed: 30846494 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):33

PubMed: 30728070 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):277

PubMed: 31653272 ( click the link to review the publication )

Elife, 2019, 10.7554/eLife.44306

PubMed: 31050342 ( click the link to review the publication )

Cell Mol Life Sci, 2019, 76(5):1005-1025

PubMed: 30599067 ( click the link to review the publication )

Cancers (Basel), 2019, 11(4)

PubMed: 30935067 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31561534 ( click the link to review the publication )

Br J Cancer, 2019, 121(12):1039-1049

PubMed: 31690832 ( click the link to review the publication )

Cancer Discov, 2019, 9(4):526-545

PubMed: 30709805 ( click the link to review the publication )

Front Immunol, 2019, 10:409

PubMed: 30915074 ( click the link to review the publication )

Mol Oncol, 2019, 10.1002/1878-0261.12607

PubMed: 31782885 ( click the link to review the publication )

J Mol Med (Berl), 2019, 97(7):957-972

PubMed: 31025088 ( click the link to review the publication )

J Immunol, 2019, 203(12):3199-3208

PubMed: 31732526 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786

PubMed: 31694931 ( click the link to review the publication )
Front Oncol, 2019, 9:579

PubMed: 31380285 ( click the link to review the publication )

Arthritis Res Ther, 2019, 21(1):50

PubMed: 30728075 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(12)

PubMed: 31234549 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4437-4449

PubMed: 30670592 ( click the link to review the publication )

Stem Cells Int, 2019, 2019:8451282

PubMed: 30992706 ( click the link to review the publication )

Int J Neuropsychopharmacol, 2019, 22(4):317-328

PubMed: 30668714 ( click the link to review the publication )

Endocrinology, 2019, 160(11):2600-2617

PubMed: 31322702 ( click the link to review the publication )

Skelet Muscle, 2019, 9(1):12

PubMed: 31113472 ( click the link to review the publication )

Biomed Pharmacother, 2019, 115:108570

PubMed: 31054509 ( click the link to review the publication )

Life Sci, 2019, 10.1016/j.lfs.2019.116583

PubMed: 31226417 ( click the link to review the publication )

Cancer Biol Ther, 2019, 20(5):700-710

PubMed: 30571927 ( click the link to review the publication )

Dev Biol, 2019, 449(2):122-131

PubMed: 30826398 ( click the link to review the publication )

Transl Oncol, 2019, 12(4):669-682

PubMed: 30849634 ( click the link to review the publication )

Tuberculosis (Edinb), 2019, 118:101861

PubMed: 31526947 ( click the link to review the publication )

PLoS One, 2019, 14(3):e0213186

PubMed: 30830950 ( click the link to review the publication )

Pain Res Manag, 2019, 2019:1648919

PubMed: 30809320 ( click the link to review the publication )

Oncotarget, 2019, 10(20):1903-1917

PubMed: 30956773 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 10.1016/j.jcmgh.2019.10.005

PubMed: 31654770 ( click the link to review the publication )

eNeuro, 2019, 6(1)

PubMed: 30783618 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):387-401

PubMed: 29200404 ( click the link to review the publication )

Nat Commun, 2018, 9(1):764

PubMed: 29472538 ( click the link to review the publication )

EMBO Rep, 2018, 19(9)

PubMed: 30021835 ( click the link to review the publication )

Int J Cancer, 2018, 143(6):1388-1401

PubMed: 29633255 ( click the link to review the publication )

Neuropsychopharmacology, 2018, 43(8):1779-1788

PubMed: 29760409 ( click the link to review the publication )
Sci Signal, 2018, 11(557)

PubMed: 30459282 ( click the link to review the publication )

Cell Death Dis, 2018, 9(6):623

PubMed: 29795376 ( click the link to review the publication )

Cell Death Dis, 2018, 9(11):1081

PubMed: 30349042 ( click the link to review the publication )

Arch Toxicol, 2018, 92(7):2227-2243

PubMed: 29845424 ( click the link to review the publication )

Basic Res Cardiol, 2018, 114(1):3

PubMed: 30446837 ( click the link to review the publication )

Oncoimmunology, 2018, 7(11):e1466018

PubMed: 30377559 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(9):2013-2023

PubMed: 29934340 ( click the link to review the publication )

Biochim Biophys Acta Mol Basis Dis, 2018, 1864(8):2610-2622

PubMed: 29684588 ( click the link to review the publication )

Oncogenesis, 2018, 7(4):36

PubMed: 29691367 ( click the link to review the publication )

J Virol, 2018, 92(6)

PubMed: 29298886 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(11)

PubMed: 30424007 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(8)

PubMed: 30081552 ( click the link to review the publication )

Sci Rep, 2018, 8(1):8492

PubMed: 29855565 ( click the link to review the publication )

Sci Rep, 2018, 8(1):12886

PubMed: 30150730 ( click the link to review the publication )

Sci Rep, 2018, 8(1):13638

PubMed: 30206377 ( click the link to review the publication )

Sci Rep, 2018, 8(1):9391

PubMed: 29925922 ( click the link to review the publication )

Sci Rep, 2018, 8(1):13072

PubMed: 30166563 ( click the link to review the publication )

Mol Pharmacol, 2018, 94(2):793-801

PubMed: 29880639 ( click the link to review the publication )

Biochem J, 2018, 475(24):3921-3932

PubMed: 30552170 ( click the link to review the publication )

Exp Cell Res, 2018, 371(1):231-237

PubMed: 30107147 ( click the link to review the publication )

Alcohol Clin Exp Res, 2018, 42(11):2160-2171

PubMed: 30103280 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2018, 82(1):65-75

PubMed: 29721849 ( click the link to review the publication )

PLoS One, 2018, 13(11):e0207915

PubMed: 30481203 ( click the link to review the publication )

PLoS One, 2018, 13(3):e0194661

PubMed: 29579087 ( click the link to review the publication )
J Med Virol, 2018, 90(9):1478-1485

PubMed: 29704439 ( click the link to review the publication )

Med Sci Monit, 2018, 24:2620-2630

PubMed: 29704392 ( click the link to review the publication )

Oncol Lett, 2018, 16(2):1967-1974

PubMed: 30008890 ( click the link to review the publication )

JCI Insight, 2018, 3(4)

PubMed: 29467324 ( click the link to review the publication )

Oncotarget, 2018, 9(92):36413-36429

PubMed: 30559927 ( click the link to review the publication )

Curr Protoc Pharmacol, 2018, 81(1):e41

PubMed: 29927058 ( click the link to review the publication )

Oncotarget, 2018, 9(39):25630-25646

PubMed: 29876013 ( click the link to review the publication )

Cond Med, 2018, 1(2):64-72

PubMed: 30135960 ( click the link to review the publication )

Oncotarget, 2018, 9(28):19597-19612

PubMed: 29731968 ( click the link to review the publication )

Oncotarget, 2018, 9(63):32182-32190

PubMed: 30181808 ( click the link to review the publication )

Data Brief, 2018, 17:1314-1319

PubMed: 29876485 ( click the link to review the publication )

Korean J Physiol Pharmacol, 2018, 22(1):23-33

PubMed: 29302209 ( click the link to review the publication )

Sci Rep, 2018, 8(1):13072

PubMed: 30166563 ( click the link to review the publication )

J Clin Invest, 2017, 127(6):2235-2248

PubMed: 28436940 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(11):6334-6349

PubMed: 28369619 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(51):E10981-E10990

PubMed: 29203668 ( click the link to review the publication )

Cell Rep, 2017, 19(4):875-889

PubMed: 28445736 ( click the link to review the publication )

Oncogene, 2017, 36(12):1707-1720

PubMed: 27694895 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(21):3865-3880

PubMed: 28832971 ( click the link to review the publication )

J Med Chem, 2017, 60(13):5334-5348

PubMed: 28581289 ( click the link to review the publication )

Plant Physiol, 2017, 175(4):1760-1773

PubMed: 29018096 ( click the link to review the publication )

Arch Toxicol, 2017, 91(5):2191-2208

PubMed: 27807597 ( click the link to review the publication )

Cell Chem Biol, 2017, 24(7):858-869

PubMed: 28669525 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )
Cancer Discov, 2017, 7(8):852-867

PubMed: 28408401 ( click the link to review the publication )

Front Immunol, 2017, 8:671

PubMed: 28659914 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(12):2689-2700

PubMed: 28802253 ( click the link to review the publication )

Mol Ther Methods Clin Dev, 2017, 6:54-65

PubMed: 28664166 ( click the link to review the publication )

Eur J Med Chem, 2017, 127:531-553

PubMed: 28109947 ( click the link to review the publication )

J Virol, 2017, 91(16)

PubMed: 28566376 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(5)

PubMed: 28481295 ( click the link to review the publication )

Sci Rep, 2017, 7(1):10921

PubMed: 28883618 ( click the link to review the publication )

Sci Rep, 2017, 7(1):12084

PubMed: 28935977 ( click the link to review the publication )

Sci Rep, 2017, 7(1):8641

PubMed: 28819194 ( click the link to review the publication )

Mech Ageing Dev, 2017, 166:6-15

PubMed: 28843433 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 361(1):140-150

PubMed: 28174211 ( click the link to review the publication )

J Neuropathol Exp Neurol, 2017, 76(12):1000-1007

PubMed: 29136455 ( click the link to review the publication )

J Endocrinol, 2017, 233(3):369-379

PubMed: 28438776 ( click the link to review the publication )

Am J Physiol Renal Physiol, 2017, 312(3):F502-F515

PubMed: 28052874 ( click the link to review the publication )

Int J Cell Biol, 2017, 2017:6169310

PubMed: 28321257 ( click the link to review the publication )

Int J Mol Med, 2017, 40(3):661-672

PubMed: 28677722 ( click the link to review the publication )

Bioorg Med Chem, 2017, 25(7):2105-2132

PubMed: 28259528 ( click the link to review the publication )

PLoS One, 2017, 12(10):e0186620

PubMed: 29045501 ( click the link to review the publication )

Connect Tissue Res, 2017, 58(1):64-75

PubMed: 27404795 ( click the link to review the publication )

Pulm Pharmacol Ther, 2017, 44:61-69

PubMed: 28315487 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:11-22

PubMed: 27761810 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:3-10

PubMed: 27761809 ( click the link to review the publication )

Oncotarget, 2017, 8(69):114156-114172

PubMed: 29371976 ( click the link to review the publication )
Oncotarget, 2017, 8(55):93825-93838

PubMed: 29212192 ( click the link to review the publication )

Oncotarget, 2017, 9(3):3172-3187

PubMed: 29423038 ( click the link to review the publication )

Oncotarget, 2017, 8(47):83155-83170

PubMed: 29137331 ( click the link to review the publication )

JCI Insight, 2017, 2(6):e90196

PubMed: 28352655 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4079-4095

PubMed: 27863422 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:375-385

PubMed: 27761836 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107076-107088

PubMed: 29291012 ( click the link to review the publication )

Sci Rep, 2017, 589:97-106

PubMed: 28273598 ( click the link to review the publication )

Nat Microbiol, 2016, 1:16174

PubMed: 27694949 ( click the link to review the publication )

Kidney Int, 2016, 89(2):317-26

PubMed: 26509586 ( click the link to review the publication )

Cancer Res, 2016, 76(10):3067-77

PubMed: 26980768 ( click the link to review the publication )

Cell Death Differ, 2016, 23(8):1312-21

PubMed: 26915294 ( click the link to review the publication )

Sci Signal, 2016, 9(422):ra34

PubMed: 27048565 ( click the link to review the publication )

J Med Chem, 2016, 59(4):1613-33

PubMed: 26681404 ( click the link to review the publication )

Clin Epigenetics, 2016, 8:76

PubMed: 27437033 ( click the link to review the publication )

Clin Epigenetics, 2016, 8:62

PubMed: 27231489 ( click the link to review the publication )

Oncoimmunology, 2016, 5(11):e1219008

PubMed: 27999738 ( click the link to review the publication )

Oncoimmunology, 2016, 5(6):e1164919

PubMed: 27471639 ( click the link to review the publication )

Osteoarthritis Cartilage, 2016, 24(8):1451-60

PubMed: 27072078 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(2):299-312

PubMed: 26772204 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(10):2432-2441

PubMed: 27474150 ( click the link to review the publication )

Pharmacol Res, 2016, 103:328-39

PubMed: 26657418 ( click the link to review the publication )

Transl Psychiatry, 2016, 6(12):e974

PubMed: 27922638 ( click the link to review the publication )

Dis Model Mech, 2016, 9(5):541-52

PubMed: 26989193 ( click the link to review the publication )
J Virol, 2016, 90(20):9018-28

PubMed: 27466424 ( click the link to review the publication )

Front Cell Neurosci, 2016, 10:221

PubMed: 27729849 ( click the link to review the publication )

Front Cell Neurosci, 2016, 9:510

PubMed: 26793062 ( click the link to review the publication )

Sci Rep, 2016, 6:38407

PubMed: 27910927 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2016, 311(1):L124-34

PubMed: 27233998 ( click the link to review the publication )

Am J Pathol, 2016, 186(10):2701-8

PubMed: 27555113 ( click the link to review the publication )

Int J Neuropsychopharmacol, 2016, 10.1093/ijnp/pyw035

PubMed: 27207921 ( click the link to review the publication )

Mol Brain, 2016, 9(1):79

PubMed: 27535553 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(5):546-57

PubMed: 27029345 ( click the link to review the publication )

BMC Cancer, 2016, 10.1186/s12885-016-2353-7

PubMed: 27188282 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2016, 142(11):2263-73

PubMed: 27576506 ( click the link to review the publication )

Biol Chem, 2016, 397(1):75-83

PubMed: 26431101 ( click the link to review the publication )

Methods Enzymol, 2016, 573:161-81

PubMed: 27372753 ( click the link to review the publication )

Sci Rep, 2016, 10.1038/srep28025

PubMed: 27320682 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71696-71702

PubMed: 27765934 ( click the link to review the publication )

Oncotarget, 2016, 7(7):7390-402

PubMed: 26862729 ( click the link to review the publication )

Gene Regul Syst Bio, 2016, 10:9-13

PubMed: 26823649 ( click the link to review the publication )

Oncotarget, 2016, 7(6):6727-47

PubMed: 26734995 ( click the link to review the publication )

Blood, 2015, 5;125(6):941-8

PubMed: 25468569 ( click the link to review the publication )

Nat Commun, 2015, 10.1038/ncomms7537

PubMed: ( click the link to review the publication )

Nat Commun, 2015, 6:7023

PubMed: 25960197 ( click the link to review the publication )

Nat Commun, 2015, 6:6537

PubMed: 26055519 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404396

PubMed: 25872941 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(14):3230-3240

PubMed: 25813020 ( click the link to review the publication )
Blood Cancer J, 2015, 5:e312

PubMed: 25978432 ( click the link to review the publication )

J Control Release, 2015, 204:20-9

PubMed: 25681050 ( click the link to review the publication )

Elife, 2015, 4

PubMed: 26701908 ( click the link to review the publication )

Cancer Lett, 2015, 366(1):32-43

PubMed: 26028172 ( click the link to review the publication )

Am J Transplant, 2015, 10.1111/ajt.13106

PubMed: 25708614 ( click the link to review the publication )

J Med Chem, 2015, 58(2):785-800

PubMed: 25490700 ( click the link to review the publication )

J Med Chem, 2015, 58(2):785-800

PubMed: ( click the link to review the publication )

Breast Cancer Res, 2015, 17:26

PubMed: 25848915 ( click the link to review the publication )

Breast Cancer Res, 2015, 17(1):533

PubMed: 25778369 ( click the link to review the publication )

J Neurosci, 2015, 35(3):1250-9

PubMed: 25609639 ( click the link to review the publication )

Br J Cancer, 2015, 112(2):329-37

PubMed: 25514379 ( click the link to review the publication )

Br J Haematol, 2015, 168(3):371-83

PubMed: 25284154 ( click the link to review the publication )

Epigenetics, 2015, 10.1080/15592294.2015.1039216

PubMed: 25923331 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(7):3984-94

PubMed: 25896701 ( click the link to review the publication )

Toxicol Sci, 2015, 148(1):220-8

PubMed: 26251326 ( click the link to review the publication )

Sci Rep, 2015, 5:16873

PubMed: 26585834 ( click the link to review the publication )

Int J Neuropsychopharmacol, 2015, 10.1093/ijnp/pyv029

PubMed: 25762717 ( click the link to review the publication )

Front Neurosci, 2015, 9:319

PubMed: 26441495 ( click the link to review the publication )

Breast Cancer Res Treat, 2015, 151(2):281-94

PubMed: 25904215 ( click the link to review the publication )

Virology, 2015, 485:340-54

PubMed: 26331681 ( click the link to review the publication )

J Appl Physiol (1985), 2015, 119(4):342-51

PubMed: 26112243 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0144660

PubMed: 26713848 ( click the link to review the publication )

PLoS One, 2015, 10(9):e0137699

PubMed: 26361334 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123901

PubMed: 25875914 ( click the link to review the publication )
Future Virol, 2015, 10(4), 351–356

PubMed: ( click the link to review the publication )

Cancer Immunol Res, 2015, 3(12):1375-85

PubMed: 26297712 ( click the link to review the publication )

Genes Cancer, 2015, 6(5-6):184-213

PubMed: 26124919 ( click the link to review the publication )

Oncotarget, 2015, 6(28):25784-800

PubMed: 26329759 ( click the link to review the publication )

Sheng Li Xue Bao, 2015, 67(5):447-54

PubMed: 26490061 ( click the link to review the publication )

Oncotarget, 2015, 6(28):25801-14

PubMed: 26317649 ( click the link to review the publication )

Sci Transl Med, 2014, 6(256):256ra135

PubMed: 25273096 ( click the link to review the publication )

Genes Dev, 2014, 28(14):1578-91

PubMed: 25030697 ( click the link to review the publication )

PLoS Biol, 2014, 12(1):e1001758

PubMed: 24409098 ( click the link to review the publication )

Int J Cancer, 2014, 10.1002/ijc.28924

PubMed: 24771510 ( click the link to review the publication )

Addict Biol, 2014, 10.1111/adb.12161.

PubMed: 25041570 ( click the link to review the publication )

Br J Haematol, 2014, 167(5):639-50

PubMed: 25155625 ( click the link to review the publication )

Mol Cancer Res, 2014, 12(1):32-7

PubMed: 24165483 ( click the link to review the publication )

J Cell Sci, 2014, 127(Pt 7):1441-53

PubMed: 24463822 ( click the link to review the publication )

Eur J Immunol, 2014, 44(8):2478-88

PubMed: 24810486 ( click the link to review the publication )

J Biol Chem, 2014, 289(14):9918-25

PubMed: 24515107 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(3):415-27

PubMed: 24248598 ( click the link to review the publication )

Retrovirology, 2014, 11:67

PubMed: 25116364 ( click the link to review the publication )

Neuromolecular Med, 2014, 16(4):727-41

PubMed: 25063076 ( click the link to review the publication )

Pharmacological Reports, 2014, 49–55

PubMed: ( click the link to review the publication )

PLoS One, 2014, 9(11):e113341

PubMed: 25409334 ( click the link to review the publication )

PLoS One, 2014, 9(9):e106784

PubMed: 25198282 ( click the link to review the publication )

PLoS One, 2014, 9(12):e115401

PubMed: 25521755 ( click the link to review the publication )

Pharmacol Rep, 2014, 66(1):49-55

PubMed: 24905306 ( click the link to review the publication )
Biochem Biophys Res Commun, 2014, 445(2):320-6

PubMed: 24530917 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7328-41

PubMed: 25193862 ( click the link to review the publication )

Oncotarget, 2014, 5(12):4516-28

PubMed: 24980831 ( click the link to review the publication )

Curr Pharm Desigh, 2014, 20(11):1874-80

PubMed: 23888956 ( click the link to review the publication )

Nat Commun, 2013, 4:2735

PubMed: 24193185 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(12):6018-33

PubMed: 23625969 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2013, 110(28):E2621-8

PubMed: 23788661 ( click the link to review the publication )

Genet Mol Biol, 2013, 36(3):299-307

PubMed: 24130434 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(1):118-27

PubMed: 23091117 ( click the link to review the publication )

Cell Rep, 2013, 5(6):1679-89

PubMed: 24360956 ( click the link to review the publication )

Haematologica, 2013, 98(1):57-64

PubMed: 22801959 ( click the link to review the publication )

Int J Cancer, 2013, 132(9):2076-86

PubMed: 23047626 ( click the link to review the publication )

J Neuroscience, 2013, 33(50):19664-76

PubMed: 24336730 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e655

PubMed: 23744355 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e951

PubMed: 24309938 ( click the link to review the publication )

Stem Cells, 2013, 31(7):1434-45

PubMed: 23592435 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(10):2078-87

PubMed: 23939379 ( click the link to review the publication )

AIDS, 2013, 27(18):2853-62

PubMed: 24189584 ( click the link to review the publication )

J Neurochem, 2013, 129(3):509-15

PubMed: 24147654 ( click the link to review the publication )

J Biol Chem, 2013, 288(20):14400-7

PubMed: 23539624 ( click the link to review the publication )

Genes Brain Behav, 2013, 13(1):69-86

PubMed: 24286462 ( click the link to review the publication )

Infect Immun, 2013, 82(2):706-19

PubMed: 24478085 ( click the link to review the publication )

Mol Reprod Dev, 2013, 154(9):1668-79

PubMed: 23693161 ( click the link to review the publication )
Pediatr Nephrol, 2013, 28(10):1909-21

PubMed: 23052657 ( click the link to review the publication )

PLoS One, 2013, 8(9):e74930

PubMed: 24058639 ( click the link to review the publication )

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086 ( click the link to review the publication )

Exp Hematol, 2013, 41(1):113-23.e2

PubMed: 22989761 ( click the link to review the publication )

Circ Res, 2012, 110(5):739-48

PubMed: 22282194 ( click the link to review the publication )

Mol Cancer Ther, 2012, 11(12):2600-9

PubMed: 23012246 ( click the link to review the publication )

J Neurochem, 2012, 123 Suppl 2:108-15

PubMed: 23050648 ( click the link to review the publication )

J Immunol, 2012, 189(4):1792-9

PubMed: 22786766 ( click the link to review the publication )

Eur Neuropsychopharmacol, 2012, 22(9):651-6

PubMed: 22341945 ( click the link to review the publication )

J Am Heart Assoc, 2012, 1(3):e000901

PubMed: 23130137 ( click the link to review the publication )

J Virol, 2012, 86(6):3073-87

PubMed: 22238308 ( click the link to review the publication )

PLoS One, 2012, 7(7):e41776

PubMed: 22848598 ( click the link to review the publication )

Biochem Biophys Res Commun, 2012, 428(1):121-6

PubMed: 23063976 ( click the link to review the publication )

Biomol Ther (Seoul), 2012, 20(1):81-8

PubMed: 24116279 ( click the link to review the publication )

Brain, 2011, 134(Pt 8):2408-21

PubMed: 21772061 ( click the link to review the publication )

J Thorac Oncol, 2011, 6(7):1152-61

PubMed: 21597390 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2011, 108(49):19629-34

PubMed: 22106282 ( click the link to review the publication )

J Neurosci, 2011, 31(11):3990-9

PubMed: 21411642 ( click the link to review the publication )

Biochem Biophys Res Commun, 2011, 414(1):25-30

PubMed: 21925145 ( click the link to review the publication )

J Biomed Biotechnol, 2011, 2011:371832

PubMed: 21151613 ( click the link to review the publication )

Sci Signal, 2010, 3(146):ra80

PubMed: 21045206 ( click the link to review the publication )

Mol Pain, 2010, 6:51

PubMed: 20822541 ( click the link to review the publication )

PLoS One, 2010, 5(12):e14335

PubMed: 21179472 ( click the link to review the publication )

PLoS One, 2010, 5(12):e14462

PubMed: 21283510 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Targets

HDAC1 ^[2] (Cell-free assay)	HDAC3 ^[2] (Cell-free assay)
0.51 μM	1.7 μM

In vitro

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21^WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. ^[1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. ^[2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
SCC-3	M1zVcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlLoTWM2OD1yLkC2NUDPxE1?	NYHtdWs2W0GQR1XS
ALL-PO	NUG1elNDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTBwME[zOVUh\|ryP	NY\6RWhzW0GQR1XS
697	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkO1TWM2OD1yLkC5PVc3KM7:TR?=	NW[wd3BtW0GQR1XS
NCI-H748	MojPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTBwMUCzN\|Qh\|ryP	M4KwenNCVkeHUh?=
NKM-1	M3frWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV3JR\|UxRTBwMUC5NVIh\|ryP	NW[wO5REW0GQR1XS
ES1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnWOGU4UUN3ME2wMlEyOjV3IN88US=>	M1TxRnNCVkeHUh?=
NCI-H1963	NEjKN5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkPlTWM2OD1yLkGxOVc6KM7:TR?=	MVvTRW5ITVJ?
NCI-H1417	MnzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPWTWM2OD1yLkGyPVc1KM7:TR?=	M2jUTHNCVkeHUh?=
NEC8	MofOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4TJcGlEPTB;MD6xN\|UzPyEQvF2=	NYHKRlE3W0GQR1XS
CRO-AP2	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTBwMU[4PFkh\|ryP	M4ntSXNCVkeHUh?=
A3-KAW	Mn\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3nTPGlEPTB;MD6xO\|YzPyEQvF2=	MVnTRW5ITVJ?
SF539	Mn:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFLOZWtKSzVyPUCuNVk2QTNizszN	MYrTRW5ITVJ?
NOS-1	Mmq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MofxTWM2OD1yLkG5OlE6KM7:TR?=	NWHkWIdbW0GQR1XS
NTERA-S-cl-D1	M2njSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWXDTHpHUUN3ME2wMlIxOTF\|IN88US=>	MoPUV2FPT0WU
COR-L88	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRTBwMkK5OVkh\|ryP	NUXpfFhWW0GQR1XS
EM-2	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFOxVoRKSzVyPUCuNlQxPzlizszN	M{ixPHNCVkeHUh?=
KARPAS-45	NGTWfItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\2TWM2OD1yLkK3PFM{KM7:TR?=	M4LpeXNCVkeHUh?=
DSH1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MonLTWM2OD1yLkK4O\|A5KM7:TR?=	MV3TRW5ITVJ?
HT-144	NGfLOINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYLkfIlYUUN3ME2wMlMxOjV4IN88US=>	NIDtcnpUSU6JRWK=
ATN-1	MkH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTBwM{C1O\|Yh\|ryP	NX70RmZyW0GQR1XS
HEL	NVjaWHJmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlvHTWM2OD1yLkOxN\|Q5KM7:TR?=	NYe2N3hSW0GQR1XS
NB12	NGHSUXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfwOVlMUUN3ME2wMlMyPzV4IN88US=>	NYPR[\|dIW0GQR1XS
LU-139	M16weWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2SwTmlEPTB;MD6zN\|UyKM7:TR?=	NH;xT5hUSU6JRWK=
J-RT3-T3-5	M3zRfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NETJdJRKSzVyPUCuN\|M4OTZizszN	MlfrV2FPT0WU
MOLT-13	NH:3[G5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTBwM{O4NUDPxE1?	NFnWPZNUSU6JRWK=
SR	NVPnepkxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTBwM{SyOlEh\|ryP	NUHieGl6W0GQR1XS
CMK	M{DXVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3f5dmlEPTB;MD6zOVczPyEQvF2=	M3:0RnNCVkeHUh?=
ES8	MonMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4nnSGlEPTB;MD6zOlAzOiEQvF2=	M{HMbHNCVkeHUh?=
LB647-SCLC	M33nO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4XuemlEPTB;MD6zOlc{KM7:TR?=	MV7TRW5ITVJ?
TE-8	NVGwSo5lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUn2c\|FDUUN3ME2wMlM3QTN3IN88US=>	MoK0V2FPT0WU
BV-173	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoHPTWM2OD1yLkO3NVIyKM7:TR?=	NVLZWnBKW0GQR1XS
DEL	M4j5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFrDUZBKSzVyPUCuN\|c1QDdizszN	NFPtVFZUSU6JRWK=
ARH-77	M2naVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVTBSGdyUUN3ME2wMlM5OTl\|IN88US=>	MXrTRW5ITVJ?
NCCIT	NHrRd4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmrETWM2OD1yLkO4OlQ6KM7:TR?=	NFrIUGZUSU6JRWK=
RPMI-8402	NFL3RZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY\JR\|UxRTBwM{i3NFEh\|ryP	MVnTRW5ITVJ?
MONO-MAC-6	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFPVe2JKSzVyPUCuN\|g4PzZizszN	Mn3CV2FPT0WU
SK-MM-2	NEH0[21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml3yTWM2OD1yLkO5PFY5KM7:TR?=	NGLDT3BUSU6JRWK=
CHP-126	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkC2TWM2OD1yLkSwNlMyKM7:TR?=	M4iwTXNCVkeHUh?=
A101D	NHXyXmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnHFTWM2OD1yLkSwN{DPxE1?	M{Xj[HNCVkeHUh?=
SCH	NIjNfG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW[4epNXUUN3ME2wMlQxOzR{IN88US=>	NFnzN4JUSU6JRWK=
NMC-G1	MkjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUHmNWJCUUN3ME2wMlQxOzZ5IN88US=>	MojrV2FPT0WU
NCI-H209	Mn;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUDZ[WpZUUN3ME2wMlQxPjF\|IN88US=>	MWTTRW5ITVJ?
MOLT-16	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVLJR\|UxRTBwNEGwNVch\|ryP	NWqzVJpYW0GQR1XS
RPMI-6666	M3jNTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnqzTWM2OD1yLkSxNVIh\|ryP	NXLSPJFNW0GQR1XS
OPM-2	M1PjNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXnJR\|UxRTBwNEG1NVMh\|ryP	NHvPW25USU6JRWK=
MRK-nu-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3T4ZmlEPTB;MD60N\|E2OyEQvF2=	NUP0OXRyW0GQR1XS
BC-1	M1n4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUPwN21oUUN3ME2wMlQ{PDB\|IN88US=>	M{mzbHNCVkeHUh?=
MHH-NB-11	NH7DblhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHfFXnVKSzVyPUCuOFM1PTNizszN	NUTSWFB3W0GQR1XS
Ramos-2G6-4C10	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWD1PI95UUN3ME2wMlQ{QDl5IN88US=>	NInmdGVUSU6JRWK=
LS-513	NX;5RZJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MorRTWM2OD1yLkS0OVAyKM7:TR?=	M{jkT3NCVkeHUh?=
K5	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE\T[WxKSzVyPUCuOFcxOjVizszN	NUOxNW14W0GQR1XS
HOP-62	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYTWZXlJUUN3ME2wMlQ5OzV6IN88US=>	M1TX[nNCVkeHUh?=
NCI-H187	M1HDXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoDYTWM2OD1yLkS5NlI4KM7:TR?=	MlrvV2FPT0WU
BE-13	M{jrVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NW\JSW5wUUN3ME2wMlQ6PjZzIN88US=>	NFKzZ5ZUSU6JRWK=
HC-1	M2fv[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NELOVVlKSzVyPUCuOVA1PzNizszN	M1q1OnNCVkeHUh?=
ACN	NYHwNY5ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M362[mlEPTB;MD61NVAzQCEQvF2=	M4PudHNCVkeHUh?=
HCC1599	NIDxSlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4jtbGlEPTB;MD61NVU4KM7:TR?=	NIDySIRUSU6JRWK=
MV-4-11	MnqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\EXmlEPTB;MD61N\|A1OSEQvF2=	MXLTRW5ITVJ?
LC-2-ad	M4Dq[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUn6[GZCUUN3ME2wMlU{PjZ\|IN88US=>	MVrTRW5ITVJ?
HL-60	M3rIPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnj4TWM2OD1yLkW0NlYyKM7:TR?=	NIfDPFNUSU6JRWK=
NB17	NETCbIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEnFSFNKSzVyPUCuOVQ{QCEQvF2=	NYr4[JZ2W0GQR1XS
TE-1	NXjvTVNUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVO0cJZ1UUN3ME2wMlU2OzB4IN88US=>	NILTSXRUSU6JRWK=
NCI-H524	NYXHUIxyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnqzTWM2OD1yLkW1OFAyKM7:TR?=	NIfVcpBUSU6JRWK=
MZ7-mel	NHLqRoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTBwNU[xNFUh\|ryP	MXrTRW5ITVJ?
L-363	NWTIb4hmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTBwNU[2OVch\|ryP	NEfKXG9USU6JRWK=
BL-41	NIrwOWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2jmZ2lEPTB;MD61Olg5QSEQvF2=	MnTiV2FPT0WU
LU-134-A	MmX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfxTWM2OD1yLkW3NFc{KM7:TR?=	NV7qV5J4W0GQR1XS
SIG-M5	NX;FeGROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUDJR\|UxRTBwNUe4OFgh\|ryP	Mk\SV2FPT0WU
ONS-76	MoHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXftc25WUUN3ME2wMlU5OjR{IN88US=>	MkDhV2FPT0WU
KARPAS-299	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnTCTWM2OD1yLkW4OVA1KM7:TR?=	MV\TRW5ITVJ?
DU-4475	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYX4ZWZIUUN3ME2wMlU5PzB\|IN88US=>	M4TYRXNCVkeHUh?=
NB69	M{Hicmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTBwNUm4NlUh\|ryP	MXfTRW5ITVJ?
MHH-PREB-1	M4XWU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGL6NIRKSzVyPUCuOlA4OTlizszN	NGHOUFRUSU6JRWK=
LU-165	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGGzelNKSzVyPUCuOlE5OTJizszN	MWTTRW5ITVJ?
LOUCY	MoTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTBwNkOzOlQh\|ryP	MXPTRW5ITVJ?
NCI-H526	M{[0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml[2TWM2OD1yLk[zOVQyKM7:TR?=	NEnTTpZUSU6JRWK=
KE-37	NV30W4FGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3X4ZWlEPTB;MD62OFI4PiEQvF2=	NVWyeno1W0GQR1XS
NALM-6	Ml:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTBwNkS4OkDPxE1?	MX;TRW5ITVJ?
CW-2	NFrjN\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXPJR\|UxRTBwNkW3PVQh\|ryP	MULTRW5ITVJ?
SU-DHL-1	Ml7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXXPU2ZwUUN3ME2wMlY2QTR5IN88US=>	M4nsXnNCVkeHUh?=
NB13	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnnUJRsUUN3ME2wMlY3QDF5IN88US=>	MoHFV2FPT0WU
QIMR-WIL	M3\YdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVnQPWtwUUN3ME2wMlY5OzR\|IN88US=>	M{ezV3NCVkeHUh?=
ECC12	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NILFcZpKSzVyPUCuO\|AxQDZizszN	NEmzVphUSU6JRWK=
KALS-1	Mm\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGPTPJVKSzVyPUCuO\|A1QTJizszN	NGrVTZRUSU6JRWK=
COR-L279	M2fCO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXvHWIp6UUN3ME2wMlcxQTl4IN88US=>	NUnlbGxNW0GQR1XS
NB14	M1zFXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTBwN{K2NVch\|ryP	MYnTRW5ITVJ?
CCRF-CEM	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXjJR\|UxRTBwN{S2OlEh\|ryP	M1[5WnNCVkeHUh?=
SW954	NEXufXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{nOS2lEPTB;MD63OVk6QSEQvF2=	MkCxV2FPT0WU
IST-SL1	NVjuOHBjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LnVmlEPTB;MD63O\|M1QCEQvF2=	M3vmOnNCVkeHUh?=
LAMA-84	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYHubmsxUUN3ME2wMlc4PTZ5IN88US=>	MXnTRW5ITVJ?
Daudi	NYD6ZW5{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvLTWM2OD1yLke3OlgyKM7:TR?=	MlK1V2FPT0WU
BC-3	NGPhdoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRTBwN{izNFgh\|ryP	M{\DRXNCVkeHUh?=
HCC2998	M2n4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTBwN{izOkDPxE1?	MWfTRW5ITVJ?
NCI-H69	MlXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYXvTZpJUUN3ME2wMlgxOTR5IN88US=>	MmrRV2FPT0WU
CPC-N	MmH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7ienZRUUN3ME2wMlgxPTJ2IN88US=>	MWHTRW5ITVJ?
NOMO-1	MlvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml;5TWM2OD1yLkixNFg1KM7:TR?=	NILiZ2JUSU6JRWK=
CESS	NFzpU2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUnJR\|UxRTBwOEGxPVch\|ryP	NWjibGNPW0GQR1XS
LC4-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nsSWlEPTB;MD64OFAxPyEQvF2=	MmX3V2FPT0WU
BL-70	NGTZUGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn3jTWM2OD1yLki1O\|AzKM7:TR?=	MVjTRW5ITVJ?
ES4	M4T0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVLJR\|UxRTBwOEW4Olgh\|ryP	M1;HdHNCVkeHUh?=
HCE-T	M4LwVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGG5OFlKSzVyPUCuPFcyPzFizszN	MXLTRW5ITVJ?
JAR	M3jwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXSybYlVUUN3ME2wMlg4QDJ5IN88US=>	NUXNU45pW0GQR1XS
ST486	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXXGcolQUUN3ME2wMlg4QTF5IN88US=>	M2jFbXNCVkeHUh?=
KS-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTBwOEiwPVYh\|ryP	NUPEbmlOW0GQR1XS
GDM-1	NX7jSmpXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4jjWmlEPTB;MD64PFY5PyEQvF2=	M3naWXNCVkeHUh?=
EHEB	NXHrdGlyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV7JR\|UxRTBwOUK1PFUh\|ryP	MYPTRW5ITVJ?
LB2518-MEL	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1[5TGlEPTB;MD65N\|I5PCEQvF2=	MlTyV2FPT0WU
GOTO	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M13YbGlEPTB;MD65OVA4PiEQvF2=	MorxV2FPT0WU
LXF-289	NHL2fohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2TsZWlEPTB;MD65OVkxOSEQvF2=	M1\meXNCVkeHUh?=
ES6	M1f5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1SyfmlEPTB;MD65OlQ{PyEQvF2=	MYfTRW5ITVJ?
OS-RC-2	MmLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkL3TWM2OD1yLkm2PFMh\|ryP	MVjTRW5ITVJ?
DMS-153	NHXIOW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\EXlJKSzVyPUCuPVc1PjlizszN	MkjPV2FPT0WU
SK-PN-DW	NWPXSGFMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEPGUHFKSzVyPUCuPVc5OzFizszN	MmXDV2FPT0WU
HH	NH:w[\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnXUTWM2OD1yLkm4PVU6KM7:TR?=	MnT3V2FPT0WU
SH-4	NEPFWVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHq2eIJKSzVyPUGuNFI1OSEQvF2=	M3u1dnNCVkeHUh?=
MOLT-4	Ml;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;KWppVUUN3ME2xMlA{PDV2IN88US=>	NUPyTWJDW0GQR1XS
TGW	NI\rdGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVviNplRUUN3ME2xMlA4Pjd3IN88US=>	MWfTRW5ITVJ?
L-540	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmC5TWM2OD1zLkGwOlA1KM7:TR?=	NGXBPGZUSU6JRWK=
PF-382	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTFwMUG1NVMh\|ryP	M1n6cnNCVkeHUh?=
LC-1F	Mle4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmH1TWM2OD1zLkGyNFA4KM7:TR?=	NUPFXVF[W0GQR1XS
OVCAR-4	NHXZTlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1:wbGlEPTB;MT6xN\|E3PSEQvF2=	NIPyNoVUSU6JRWK=
A4-Fuk	NX7FbHRZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3m1S2lEPTB;MT6xOVM3PCEQvF2=	NF;6emFUSU6JRWK=
HCC2218	NYLTVG52T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2SwdGlEPTB;MT6xOlY1OSEQvF2=	Mn7HV2FPT0WU
HAL-01	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3:1bGlEPTB;MT6xOlk1OyEQvF2=	NY\sNnpPW0GQR1XS
IST-MEL1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRTFwMUe2OVkh\|ryP	NFHNeXFUSU6JRWK=
NCI-H719	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTFwMUe4PVgh\|ryP	MU\TRW5ITVJ?
EVSA-T	M3zyT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTFwMUixNVQh\|ryP	M3XTUnNCVkeHUh?=
SK-NEP-1	M2XoUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlzzTWM2OD1zLkKwNlY3KM7:TR?=	NWjLdYdZW0GQR1XS
OCUB-M	NITKS\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFuwSY9KSzVyPUGuNlE1QDlizszN	M1;LSHNCVkeHUh?=
MEG-01	NFHlS5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYXJR\|UxRTFwMkKxNVgh\|ryP	M37iR3NCVkeHUh?=
no-10	MoLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTFwMkOxNVIh\|ryP	NVv6UpRCW0GQR1XS
MHH-CALL-2	M4qzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV:wcoN2UUN3ME2xMlI1PzJzIN88US=>	MkfQV2FPT0WU
SK-N-DZ	M1nqN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTFwMkS3O\|Yh\|ryP	NH7E[GRUSU6JRWK=
SCLC-21H	NIDXRYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\WTWM2OD1zLkK2OFc5KM7:TR?=	MoG1V2FPT0WU
CTV-1	NYWwclR5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIjyPVFKSzVyPUGuNlc1OjVizszN	M{jDN3NCVkeHUh?=
NB1	MnPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2PCb2lEPTB;MT6yO\|c{OiEQvF2=	NV7SfZZKW0GQR1XS
NCI-H64	MmPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLVTWM2OD1zLkK4OFYzKM7:TR?=	NUSwXmdiW0GQR1XS
MDA-MB-134-VI	M4HMOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYfJR\|UxRTFwMki1O\|ch\|ryP	M2rGWHNCVkeHUh?=
LB2241-RCC	MlPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn24TWM2OD1zLkK4OlY{KM7:TR?=	MoDyV2FPT0WU
8-MG-BA	NILMSmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIi5U4JKSzVyPUGuNlg5PjZizszN	MVfTRW5ITVJ?
LP-1	NH7FUJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;Cc2lEPTB;MT6yPVk1PyEQvF2=	M1LYeXNCVkeHUh?=
LS-411N	NWHhbo5mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH7RNmVKSzVyPUGuN\|A6QThizszN	MVXTRW5ITVJ?
CAL-148	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFnPSGpKSzVyPUGuN\|I2PDJizszN	M125OXNCVkeHUh?=
NCI-H2171	MnHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUPmN4c4UUN3ME2xMlM1PTB{IN88US=>	MmO4V2FPT0WU
JiyoyeP-2003	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{HScGlEPTB;MT6zOVM6KM7:TR?=	M{GxPHNCVkeHUh?=
NCI-H2107	Mo\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVXJR\|UxRTFwM{W4PFMh\|ryP	NED4[5JUSU6JRWK=
BB30-HNC	NFnENHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2S5fGlEPTB;MT6zPFk4QCEQvF2=	MVnTRW5ITVJ?
K-562	MnO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG\mTWVKSzVyPUGuN\|kzOTlizszN	NFn5OY9USU6JRWK=
PSN1	NUDyPJVET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV\JR\|UxRTFwNEKyPFch\|ryP	M1H6[XNCVkeHUh?=
HCC2157	M3XqOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\HTWM2OD1zLkSyOlkyKM7:TR?=	NGnXe\|JUSU6JRWK=
SBC-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M37MbmlEPTB;MT60Nlc1OSEQvF2=	NF:5ZXBUSU6JRWK=
MC116	NIrYcplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHHLTmtKSzVyPUGuOFM3OTVizszN	NWLMNoFxW0GQR1XS
KARPAS-422	NWTRRXRoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX\JR\|UxRTFwNEWzOVgh\|ryP	MVHTRW5ITVJ?
LB996-RCC	M3Pyd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTJO44zUUN3ME2xMlQ4OTB\|IN88US=>	MlvrV2FPT0WU
MSTO-211H	NEHpT4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYrtTFVFUUN3ME2xMlQ4QTh5IN88US=>	MW\TRW5ITVJ?
BT-474	M1nyOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWjTVHcyUUN3ME2xMlUyPzZ2IN88US=>	MmfJV2FPT0WU
A388	MkXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;5fGRKSzVyPUGuOVE6PDVizszN	NH:2VZJUSU6JRWK=
SJSA-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGL1OXdKSzVyPUGuOVIzPiEQvF2=	M3vqWHNCVkeHUh?=
COLO-829	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml:2TWM2OD1zLkWzOVY1KM7:TR?=	M{DRZXNCVkeHUh?=
KM-H2	MlnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4DJ[GlEPTB;MT61OlY4KM7:TR?=	MXvTRW5ITVJ?
GR-ST	NV3m[Vk4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4nMW2lEPTB;MT61OlgzKM7:TR?=	NYezclR4W0GQR1XS
RPMI-8866	NV3pOo1RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M12xOGlEPTB;MT62NFE1PCEQvF2=	MlPBV2FPT0WU
KG-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIO0TlZKSzVyPUGuOlE6ODFizszN	NEDCOllUSU6JRWK=
NCI-H82	M4\Hdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLaTWM2OD1zLk[zOFA3KM7:TR?=	Mny3V2FPT0WU
LB1047-RCC	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHLtfFlKSzVyPUGuOlM1PTlizszN	Mn3OV2FPT0WU
KM12	M2X3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFi5R2dKSzVyPUGuOlQ4KM7:TR?=	NW\PUGpKW0GQR1XS
NB5	NYjuO4dkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\BeVhCUUN3ME2xMlY2Pjd5IN88US=>	M3XETHNCVkeHUh?=
HDLM-2	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4TQV2lEPTB;MT62PFI5OSEQvF2=	M3:2[3NCVkeHUh?=
KU812	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEKzVHFKSzVyPUGuOlk3ODVizszN	MnnuV2FPT0WU
DB	MnjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVj5Z\|dSUUN3ME2xMlcxOzV\|IN88US=>	NWG3ZlhnW0GQR1XS
HD-MY-Z	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYrJR\|UxRTFwN{WyN\|Qh\|ryP	MYLTRW5ITVJ?
KURAMOCHI	MlTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmLhTWM2OD1zLke3NlA4KM7:TR?=	NVHvXnpCW0GQR1XS
ETK-1	NYOwNohST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTFwN{i4O\|kh\|ryP	NWjKdItYW0GQR1XS
SK-UT-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX3K[olQUUN3ME2xMlc6Ozh6IN88US=>	MXjTRW5ITVJ?
HUTU-80	MkXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1L3eGlEPTB;MT63PVUxQCEQvF2=	M{DpTXNCVkeHUh?=
ES7	M{HOUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTFwOECzNFIh\|ryP	NU\pPWJJW0GQR1XS
SW872	M2fqUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTFwOEGzPVUh\|ryP	MnjDV2FPT0WU
TK10	NHX5XZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTFwOEOxNFgh\|ryP	MYjTRW5ITVJ?
LB831-BLC	NVXFTGhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFm2eYJKSzVyPUGuPFM2PjNizszN	NE\JXGdUSU6JRWK=
TE-9	MlXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVfHZ\|JFUUN3ME2xMlg1PDJ{IN88US=>	M1vvVnNCVkeHUh?=
MLMA	MojaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV7JR\|UxRTFwOEiyN\|Qh\|ryP	M2XoZ3NCVkeHUh?=
D-542MG	NF\kOHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PPdWlEPTB;MT64PVM4OyEQvF2=	NI\2OmRUSU6JRWK=
EW-16	NX7ub2RJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPl[5I4UUN3ME2xMlkzPzJizszN	MWDTRW5ITVJ?
LOXIMVI	MlvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIH4fpZKSzVyPUGuPVMzQCEQvF2=	MXrTRW5ITVJ?
GB-1	MmrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTFwOUO4OlYh\|ryP	MkLHV2FPT0WU
IST-SL2	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3TOXGlEPTB;Mj6wNFI3OiEQvF2=	MVfTRW5ITVJ?
LAN-6	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXW0XIY3UUN3ME2yMlAyQTZ4IN88US=>	Mkj5V2FPT0WU
NCI-H510A	NYrmV5pwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\pbI9LUUN3ME2yMlA1PTB{IN88US=>	MlXGV2FPT0WU
NCI-H1092	M2HY[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTQTWM2OD1{LkC1NVI1KM7:TR?=	MX\TRW5ITVJ?
HT	MnvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF3abYxKSzVyPUKuNVA1PTRizszN	MV;TRW5ITVJ?
RL95-2	MlvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLlbGVHUUN3ME2yMlEyPDh{IN88US=>	NULMWFhNW0GQR1XS
NCI-H1355	NYPMdY5RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn3DTWM2OD1{LkGxO\|kzKM7:TR?=	MX;TRW5ITVJ?
NCI-H720	Ml3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTJwMU[4O\|Mh\|ryP	MorIV2FPT0WU
NCI-H1522	NW\VdVR5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHz4NY5KSzVyPUKuNlE4OjNizszN	M4ThN3NCVkeHUh?=
LB373-MEL-D	NYO4RpY6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MojDTWM2OD1{LkK2PVAzKM7:TR?=	MUDTRW5ITVJ?
DG-75	MoHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3;3W2lEPTB;Mj6yO\|E1QCEQvF2=	NV;KbYNxW0GQR1XS
ML-2	M3;UXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI\sWGZKSzVyPUKuN\|I5PTVizszN	M1faSXNCVkeHUh?=
SF126	M{PDdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlrqTWM2OD1{LkOzNFk1KM7:TR?=	MY\TRW5ITVJ?
MPP-89	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{OwRWlEPTB;Mj6zN\|E1PSEQvF2=	NYX2OXZyW0GQR1XS
NCI-H345	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTJwM{OyO\|ch\|ryP	NXvzWFQ4W0GQR1XS
LS-123	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWjXU2U5UUN3ME2yMlM1QTN4IN88US=>	MUTTRW5ITVJ?
NB10	MnrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWjKWYY6UUN3ME2yMlQyODl{IN88US=>	NInRemZUSU6JRWK=
CGTH-W-1	NHyxdJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2rXRmlEPTB;Mj60NlI3PyEQvF2=	NXj3TZNMW0GQR1XS
CP66-MEL	NXXLUmhoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnn5TWM2OD1{LkS3O\|ch\|ryP	NXLYU3dpW0GQR1XS
L-428	NFPTTHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWPJR\|UxRTJwNEi1NlEh\|ryP	MVLTRW5ITVJ?
DMS-79	NYPVRYZJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTJwNUSxNFMh\|ryP	NYriZoRxW0GQR1XS
NCI-H1882	M{PEdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFj3d\|BKSzVyPUKuOlc2PjJizszN	NFq2TotUSU6JRWK=
KGN	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\4TWM2OD1{Lke2PFc3KM7:TR?=	M3joSnNCVkeHUh?=
EW-1	NXu4fIdoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXLKNmJ[UUN3ME2yMlc4ODh\|IN88US=>	MnLPV2FPT0WU
U-266	NIHNWZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3rhWWlEPTB;Mj64OFgzOyEQvF2=	NHGwc\|FUSU6JRWK=
COLO-320-HSR	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkL6TWM2OD1{Lki1OlQyKM7:TR?=	Ml;DV2FPT0WU
KMOE-2	MlfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTJwOEe3NVEh\|ryP	NUC0OlUxW0GQR1XS
BB49-HNC	NY\HR5lRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTJwOUK0PEDPxE1?	NX3UPWU6W0GQR1XS
GI-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTJwOUK5OVch\|ryP	MU\TRW5ITVJ?
NCI-H1304	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2TuSmlEPTB;Mz6wNFUyOSEQvF2=	NGfwcFdUSU6JRWK=
NCI-H2227	M{H2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1j1UmlEPTB;Mz6wNlA4QSEQvF2=	M4Twe3NCVkeHUh?=
U-87-MG	M3W4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{jIdGlEPTB;Mz6wN\|UyOyEQvF2=	M3j5WHNCVkeHUh?=
NCI-H747	M{\W[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkXaTWM2OD1\|LkC1NlA3KM7:TR?=	M4TDXXNCVkeHUh?=
CTB-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnxVIk1UUN3ME2zMlA2Ozd4IN88US=>	NYXESXpmW0GQR1XS
RPMI-8226	NFfvTGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTNwMUSzO\|gh\|ryP	M1HQTHNCVkeHUh?=
NCI-H2141	NEDEUZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYTNdWY5UUN3ME2zMlE3PTZ4IN88US=>	M3\kdXNCVkeHUh?=
IST-MES1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTNwMUiyO\|kh\|ryP	NWXHNmw4W0GQR1XS
TE-5	NUDHeZdRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmK4TWM2OD1\|LkKxN\|QzKM7:TR?=	M1rSSnNCVkeHUh?=
UACC-257	Mlu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTNwNEO2OVkh\|ryP	MlnDV2FPT0WU
SK-N-FI	NXnZTnFUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTNwNEWyNlch\|ryP	Mn3vV2FPT0WU
MFH-ino	NEnjcZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlPtTWM2OD1\|LkS2OVg6KM7:TR?=	NGTDeVhUSU6JRWK=
SF268	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoG5TWM2OD1\|LkS4NVc1KM7:TR?=	NWSxUotKW0GQR1XS
TE-12	NGDoRZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTNwNUG2PVkh\|ryP	M2fVZnNCVkeHUh?=
NB6	NF72TJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTNwNUW1OlMh\|ryP	MnH3V2FPT0WU
DJM-1	M1HHU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3;ub2lEPTB;Mz61PVg6QSEQvF2=	MmrLV2FPT0WU
MZ1-PC	MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1f0e2lEPTB;Mz62NVYzPCEQvF2=	NWG2fmlHW0GQR1XS
OCI-AML2	M3Tlcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEfWVXNKSzVyPUOuOlI3PzFizszN	NYfiWFc4W0GQR1XS
NCI-H1155	MlfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTNwN{C5OFch\|ryP	M4S2eHNCVkeHUh?=
RKO	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUSzN2RiUUN3ME2zMlc4OTh7IN88US=>	NEPnW5VUSU6JRWK=
ECC4	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWLJTI91UUN3ME2zMlk4OTl3IN88US=>	M4q1SXNCVkeHUh?=
BB65-RCC	NULDXYM2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M323T2lEPTB;Mz65O\|U1PyEQvF2=	NVX5e5pFW0GQR1XS
EB-3	NYezRoN6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV3JR\|UxRTNwOUm2N\|Mh\|ryP	MXjTRW5ITVJ?
SHP-77	NUnEbm5QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\jSllKSzVyPUSuNFA2OjRizszN	NWf5T2dxW0GQR1XS
NCI-H2196	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVuxV5hTUUN3ME20MlA2PjJ3IN88US=>	NHuwUVZUSU6JRWK=
GI-ME-N	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\VOmZlUUN3ME20MlA3Ozl7IN88US=>	MYTTRW5ITVJ?
MN-60	MnvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4fwNGlEPTB;ND6xNFg4KM7:TR?=	MnnCV2FPT0WU
NCI-H1694	NUD5cZc3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTRwMUO0NFUh\|ryP	M{jscXNCVkeHUh?=
LU-65	NXjMb\|UxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH3xeIVKSzVyPUSuNVU{OzJizszN	NXHUdGZIW0GQR1XS
NCI-H1436	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWHOZ2dkUUN3ME20MlE5OzN\|IN88US=>	MY\TRW5ITVJ?
KINGS-1	M1z4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVLJR\|UxRTRwM{G0N\|Ih\|ryP	NYHrcmd[W0GQR1XS
GT3TKB	NHu1fW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIHJeGxKSzVyPUSuN\|MzPjhizszN	MnjpV2FPT0WU
Becker	MmXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\UeWlEPTB;ND6zO\|MyOiEQvF2=	NWfaSmxYW0GQR1XS
HCC1187	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInzOJNKSzVyPUSuPFk3PTdizszN	MU\TRW5ITVJ?
D-502MG	MoH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3foeWlEPTB;NT6wNFQyPiEQvF2=	NVL2NXFuW0GQR1XS
VA-ES-BJ	NFvtc4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU\JR\|UxRTVwMUO3O\|gh\|ryP	MnL6V2FPT0WU
NB7	M2D4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTVwMUSxNVIh\|ryP	MlTyV2FPT0WU
SW962	NWnoZ4VpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTVwM{i4NVQh\|ryP	NHroc\|FUSU6JRWK=
no-11	NGrCVVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF3qUnpKSzVyPUWuO\|Y{PDNizszN	MULTRW5ITVJ?
KNS-81-FD	NELyOYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGf0TGhKSzVyPUWuPVA3QTRizszN	MkfnV2FPT0WU
COLO-684	M4LBT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1u2dmlEPTB;NT65PVQ6PCEQvF2=	M{LwOnNCVkeHUh?=
D-263MG	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3zjcWlEPTB;Nj6wPFg6PSEQvF2=	MWXTRW5ITVJ?
EW-24	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3PFTmlEPTB;Nj6yPFUyKM7:TR?=	M2XH[3NCVkeHUh?=
TE-10	NV6yb5NrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHTeFVKSzVyPU[uOFI3OjNizszN	MUnTRW5ITVJ?
EKVX	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{WxNGlEPTB;Nj60OlMzOSEQvF2=	M{fkWXNCVkeHUh?=
NCI-H1648	Mnm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1LZdGlEPTB;Nj62O\|U2PyEQvF2=	NWr3UmRoW0GQR1XS
LB771-HNC	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{P2bmlEPTB;Nj65NlMxOSEQvF2=	MnrxV2FPT0WU
SK-MEL-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3LNUmlEPTB;OD6xN\|E3PiEQvF2=	M{nXWnNCVkeHUh?=
COLO-668	M1ztemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoK0TWM2OD16LkK3O\|g3KM7:TR?=	NWDtU4g5W0GQR1XS
EW-12	M3Tkbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvKTYFKSzVyPUiuOFA5ODNizszN	M{TZXnNCVkeHUh?=
A253	NVWzcVNlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkD0TWM2OD16Lki0OlYyKM7:TR?=	MlfiV2FPT0WU
NCI-H2126	MkDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1fueWlEPTB;OD64PVMyQSEQvF2=	NYexdJFTW0GQR1XS
Calu-6	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1:4OWlEPTB;OD65PVA1OiEQvF2=	M1G1fXNCVkeHUh?=
NCI-H23	MnG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXTxS\|k3UUN3ME25MlE4PzR4IN88US=>	NIXo[llUSU6JRWK=
WSU-NHL	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIm5PHBKSzVyPUmuO\|c1PzhizszN	MVfTRW5ITVJ?
MMAC-SF	NXm0W4NDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\kdZhrUUN3ME25Mlk4QTB2IN88US=>	NIS1dm5USU6JRWK=
SK-LMS-1	M3HGemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHXjdWJKSzVyPUGwMlI5OzRizszN	M2XUUHNCVkeHUh?=
GCIY	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlmyTWM2OD1zMD61PVI1KM7:TR?=	M3Tme3NCVkeHUh?=
TE-15	NIfj[JRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkDrTWM2OD1zMT62NFA1KM7:TR?=	NWT6emFOW0GQR1XS
EoL-1-cell	NYPWeJllT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1nSdWlEPTB;MUGuO\|Y5OiEQvF2=	NF7rNJlUSU6JRWK=
NCI-H2081	Mnr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2P3RmlEPTB;MUGuO\|c5PiEQvF2=	MY\TRW5ITVJ?
EW-3	M1zB[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M17RdGlEPTB;MUKuNlQ3OyEQvF2=	M1f0d3NCVkeHUh?=
CAS-1	Mk[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTF{LkO2N\|Eh\|ryP	MWHTRW5ITVJ?
C2BBe1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHfte5RKSzVyPUGyMlYyOzFizszN	NIrkTHJUSU6JRWK=
D-247MG	M3;3XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;lbGhQUUN3ME2xNk44QTV{IN88US=>	M1PidXNCVkeHUh?=
NCI-SNU-5	M{\QWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTF{LkiwNVMh\|ryP	M4POPHNCVkeHUh?=
LS-1034	MlroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mln5TWM2OD1zND6zPVc2KM7:TR?=	M{\5c3NCVkeHUh?=
EW-18	MlXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnP4TWM2OD1zND60OFgh\|ryP	NF7mU5lUSU6JRWK=
Raji	M3PVOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\sXGlEPTB;MUSuOVA1QSEQvF2=	NWq2VINDW0GQR1XS
D-283MED	M1;E[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{m2cGlEPTB;MUSuOlI4OSEQvF2=	M3\3dnNCVkeHUh?=
MZ2-MEL	Mk\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NELvRXpKSzVyPUG0Mlk3QTZizszN	M3TidHNCVkeHUh?=
NCI-SNU-16	NHvMTHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX\JR\|UxRTF3LkS2N\|Mh\|ryP	NXi5dYhTW0GQR1XS
P30-OHK	M2TObmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoXETWM2OD1zNz63PFMyKM7:TR?=	MUPTRW5ITVJ?
RXF393	NIHCV2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTF7LkCxPFYh\|ryP	MV\TRW5ITVJ?
NCI-H1395	M3vjTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWPJR\|UxRTJyLk[3NFMh\|ryP	MlzCV2FPT0WU
U-698-M	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfL[2xKSzVyPUKwMlcxPzVizszN	NVz2VWZiW0GQR1XS
NCI-SNU-1	M{npOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlPaTWM2OD1{MD63NlI{KM7:TR?=	M3LlfHNCVkeHUh?=
SW684	MlLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnT5TWM2OD1{MT6xO\|E3KM7:TR?=	NVXXUoliW0GQR1XS
NCI-H716	MnvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTJzLkOxOVQh\|ryP	Mn3rV2FPT0WU
JVM-2	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYrNWlFnUUN3ME2yNU41OTN\|IN88US=>	NIHGRXRUSU6JRWK=
NCI-H1581	NIHwZoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEHDUHJKSzVyPUKyMlQyPDhizszN	MkXQV2FPT0WU
CA46	M4DDcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2\T[mlEPTB;M{GuOlk{PiEQvF2=	NEDURmtUSU6JRWK=
SNB75	MoT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFiyeWlKSzVyPUOzMlY2ODNizszN	MkL6V2FPT0WU
KNS-42	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M324R2lEPTB;M{WuPVYzPCEQvF2=	NGrRXIpUSU6JRWK=
TUR	MmrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfJTWM2OD1\|Nj6wOVIyKM7:TR?=	NF7JPYpUSU6JRWK=
REH	MnLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3ToemlEPTB;M{euPFIyOSEQvF2=	NXjTfFUzW0GQR1XS
EW-22	M1O1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYLIUYF6UUN3ME20Nk4zQDh3IN88US=>	MYrTRW5ITVJ?
NCI-H446	MmjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MljnTWM2OD12Mj63PFU{KM7:TR?=	Ml7aV2FPT0WU
ES3	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXqwUVYzUUN3ME20N{4yOzN7IN88US=>	M13Pd3NCVkeHUh?=
EW-11	NFzTUIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYDxdW9rUUN3ME20OE45OjF6IN88US=>	M{XZWXNCVkeHUh?=
RH-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmPsTWM2OD12Nz61PFEzKM7:TR?=	MYDTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	AcH3 / AcH4 / HDAC1 / HDAC2 / HDAC3; PubMed: 24203492 Pharm Res HCT-15 or fresh primary NK cells were treated with entinostat for 24 h, and AcH3, AcH4, and HDAC1, 2, and 3 were detected by Western blotting. Cleaved PARP; PubMed: 19148581 J Neurooncol Induction of PARP cleavage in Daoy cells upon exposure to MS-275 was demonstrated by Western blot analyses using antibodies that recognize the cleaved 89 kDa PARP protein. Pan-Actin (45 kDa) was used as a loading control. Caspase 8 ; PubMed: 19148581 J Neurooncol Cleavage of pro-Caspase-8 was demonstrated by Western blotting with extracts prepared from Daoy cells treated with 2.5 µM MS-275 for various time periods. Antibodies specific to human Caspase-8 or the loading control, pan-Actin were used to probe protein expression. DR4 / DR5; PubMed: 19148581 J Neurooncol Western blotting to detect DR4 and DR5 expression upon treatment of Daoy cells with 2.5 µM MS-275 for 4, 8 and 24 h. TopoIIα / TopoIIβ; PubMed: 21254166 Hepatology Upper panel, concentration-dependent effects of AR42, MS-275 and vorinostat on the expression of topoIIα versus topoIIβ after 48 h. Lower panel, time-dependent effect of 0.5 μM AR42 and 5 μM MS-275 on topoIIα versus topoIIβ expression in PLC-5 cells.	24203492 19148581 21254166
Immunofluorescence	phalloidin / snail; PubMed: 29855565 Sci Rep (C) Effect of MS-275 treatment on Snail expression and localization. MCs (mesothelial cells) were treated with MS-275 (250 nM), or DMSO for 48 hr and then stimulated with TGFβ1 (2 ng/ml) for 24 h before processing for immunofluorescence with a monoclonal antibody against Snail. Cell nuclei are shown in blue (Hoechst 33342). Confocal images are shown from one representative experiment of three performed. DR4 / DR5; PubMed: 19148581 J Neurooncol Flow Cytometry to measure cell surface expression of FAS, DR4 and DR5 using PE-labeled antibodies. Cells stained with isotype matched anti-human IgG antibodies served as controls. H3K4Me3 / H3K9Me3; PubMed: 22468166 Mol Cell Pharmacol Immunocytochemical analysis of the effects of AR42, SAHA, and MS-275 at the indicated concentrations on H3K4Me3 (upper panels) and H3K9Me3 (lower panels) after 24 h of treatment in LNCaP cells.	29855565 19148581 22468166
Growth inhibition assay	Cell proliferation; PubMed: 24203492 Pharm Res (A) HCT-15 cells were cultured in indicated concentrations of entinostat for up to 72 h, and proliferation determined by MTT assay as indicated. (B) HCT-15, CCH-OS-D, COL and HOS cells were cultured in indicated concentrations of entinostat for 72 h, and viable cell number was determined using the Vi-cell assay and proliferation index calculated. (C) Freshly-isolated human NK cells were cultured in indicated concentrations of entinostat for up to 72 h, and viability was assessed by flow cytometry for 7-AAD uptake. , P < 0.05, ; P ≤ 0.01; **, P ≤ 0.001 Cell viability; PubMed: 28969017 Oncotarget PANC-1, MIA PaCa-2, BxPC3, CFPAC-1, SUIT2 and SUIT2 Clone 1 cells were plated at a density of 3-5×103 per well in 96-well microtiter plates, allowed to adhere overnight and incubated for 72 hours in the presence of variable concentrations of entinostat (0-100μM). Cell viability was determined by XTT assays. The data presented are the mean values from triplicate wells from two independent experiments ±SE.	24203492 28969017
ELISA	GCP-2 / MCP-2 / MIF ; PubMed: 24241152 Molecules MS-275 and SAHA suppressed the secretion of GCP-2, MCP-2 and MIF in E11 cells. (A) GCP suppression. (B) MCP-2 suppression. (C) MIF suppression. E11 cells were incubated with HDAC inhibitors at various concentrations for 1 h before they were stimulated by LPS. 24 h later, the secretion of GCP-2, MCP-2 and MIF were quantified by ELISA (n = 8). Bars show the mean and SD in (A–C).	24241152

In vivo

MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. ^[1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. ^[4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. ^[5]

Protocol

Kinase Assay: ^[6]	- Collapse Standard HDAC Assays: Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λ_ex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. K_m and V_max values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
Cell Research: ^[2]	- Collapse Cell lines: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells Concentrations: ~ 10 μM Incubation Time: 3 days Method: Cancer cells (5 × 10³) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO₂-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na₂HPO₄ is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice. Dosages: 12.3, 24.5 and 49 mg/kg Administration: Administered orally once daily 5 days per week for 4 weeks (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	75 mg/mL (199.25 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Entinostat (MS-275) SDF

Molecular Weight	376.41
Formula	C₂₁H₂₀N₄O₃
CAS No.	209783-80-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	SNDX-275
Smiles	C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-09-01)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03829930	Recruiting	Drug: Entinostat\|Drug: Enzalutamide	Prostate Adenocarcinoma	George Washington University	May 1 2019	Phase 1
NCT03765229	Recruiting	Drug: Entinostat\|Drug: Pembrolizumab	Melanoma	UNC Lineberger Comprehensive Cancer Center\|Syndax Pharmaceuticals Inc.	March 22 2019	Phase 2
NCT03473639	Recruiting	Drug: Entinostat\|Drug: Capecitabine	Metastatic Breast Cancer\|Breast Cancer	University of Virginia\|Syndax Pharmaceuticals	January 29 2019	Phase 1
NCT03361800	Active not recruiting	Drug: Entinostat	Breast Cancer\|Invasive Breast Cancer\|ER-Negative PR-Negative HER2-Negative Breast Cancer	UNC Lineberger Comprehensive Cancer Center\|Syndax Pharmaceuticals\|National Cancer Institute (NCI)	November 28 2018	Early Phase 1
NCT03192111	Completed	Drug: Entinostat	Renal Impairment\|Healthy Volunteer	Syndax Pharmaceuticals	July 27 2017	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I would like to use Entinostat（Catalog No.S1053） for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?
Answer:
2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Selective HDAC Inhibitor

RGFP966 : HDAC3-selective, IC50=80 nM.
Selective HDAC Inhibitor

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) : Approved by FDA against cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products

LMK-235 ^New

LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.
CAY10603 ^New

CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202) ^New

4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Panobinostat (LBH589)

Panobinostat (LBH589, NVP-LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Panobinostat (LBH589) induces autophagy and apoptosis. Panobinostat effectively disrupts HIV latency in vivo. Phase 3.
Vorinostat (SAHA)

Vorinostat (suberoylanilide hydroxamic acid, SAHA, MK0683) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay. Vorinostat abrogates productive HPV-18 DNA amplification.
Trichostatin A (TSA)

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Romidepsin (FK228, Depsipeptide)

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively. Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.

Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
RGFP966

RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold). Tubastatin A promotes autophagy and increases apoptosis.
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103, MG0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Mocetinostat (MGCD0103) induces apoptosis and autophagy. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Entinostat (MS-275)